Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Current Assets (2021 - 2025)

Krystal Biotech's Current Assets history spans 5 years, with the latest figure at $1.0 billion for Q4 2025.

  • For Q4 2025, Current Assets rose 38.08% year-over-year to $1.0 billion; the TTM value through Dec 2025 reached $1.0 billion, up 38.08%, while the annual FY2025 figure was $1.0 billion, 38.08% up from the prior year.
  • Current Assets for Q4 2025 was $1.0 billion at Krystal Biotech, up from $925.6 million in the prior quarter.
  • Across five years, Current Assets topped out at $1.0 billion in Q4 2025 and bottomed at $345.8 million in Q3 2021.
  • The 5-year median for Current Assets is $533.1 million (2023), against an average of $576.0 million.
  • The largest annual shift saw Current Assets dropped 18.85% in 2023 before it skyrocketed 69.44% in 2024.
  • A 5-year view of Current Assets shows it stood at $442.3 million in 2021, then fell by 13.22% to $383.8 million in 2022, then surged by 53.19% to $587.9 million in 2023, then increased by 26.22% to $742.0 million in 2024, then soared by 38.08% to $1.0 billion in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Current Assets are $1.0 billion (Q4 2025), $925.6 million (Q3 2025), and $841.3 million (Q2 2025).